As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results